GUT MICROBIOTA–PHYTOCHEMICAL INTERACTIONS IN ULCERATIVE COLITIS: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES

The mucosal inflammatory network which drives ulcerative colitis involves a series of biological interactions between epithelial barrier injury, microbial dysbiosis, defective microbial metabolism, immune activation, oxidative stress and impaired restitutaion. The relevance of phytochemicals to this disease is not one of general “anti-inflammatory” activity, but rather by their ability to reach the colonic lumen at pharmacologically relevant concentrations, to undergo microbial biotransformation and to alter the output of microbial metabolites, and to act directly at epithelial and immune interfaces that define the pathology of ulcerative colitis. The most coherent evidence for translation into clinical practice for curcumin includes in combination with mesalamine, curcumin formulations enhanced by bioenhancing agents, resveratrol in small randomized trials, indigo naturalis, and Curcumin–QingDai. The best mechanistic evidence is based on microbial tryptophan metabolism, aryl hydrocarbon receptor signalling, interleukin 22 dependent epithelial repair, urolithin formation from ellagitannins, Nrf2 mediated redox defence, nuclear factor kappa B suppression, attenuation of the inflammasome, preservation of the mucus barrier, restoration of tight junctions and partial recovery of some short chain fatty acid producing microbial functions. In this review, we have collected the recent primary and translational studies available on microbiota/phytochemical interactions and merged them with compound-specific clinical and mechanistic evidence to suggest a development framework for precision medicine, including colonic exposure, microbial metabotype, mucosal pharmacodynamics, biomarker response, endoscopic healing, histology, and safety surveillance. The therapeutic window is optimum when phytochemicals are designed as colon targeted, microbiotically dependent pharmacologic interventions, instead of as broad-based anti-inflammatory dietary supplements.

Authors

Publication Details

Journal
European Journal Pharmaceutical and Medical Research
Published
2026-09-10
DOI
https://doi.org/10.5281/zenodo.22687747
Primary Topic
Pomegranate: compositions and health benefits
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

GUT MICROBIOTA–PHYTOCHEMICAL INTERACTIONS IN ULCERATIVE COLITIS: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES

ED Padma, Balakoti Erothi*, Routhu Pratyusha, K Eswar Kumar
European Journal Pharmaceutical and Medical Research
Pomegranate: compositions and health benefits
article

GUT MICROBIOTA–PHYTOCHEMICAL INTERACTIONS IN ULCERATIVE COLITIS: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES

ED Padma, Balakoti Erothi*, Routhu Pratyusha, K Eswar Kumar
article en

Abstract

The mucosal inflammatory network which drives ulcerative colitis involves a series of biological interactions between epithelial barrier injury, microbial dysbiosis, defective microbial metabolism, immune activation, oxidative stress and impaired restitutaion. The relevance of phytochemicals to this disease is not one of general “anti-inflammatory” activity, but rather by their ability to reach the colonic lumen at pharmacologically relevant concentrations, to undergo microbial biotransformation and to alter the output of microbial metabolites, and to act directly at epithelial and immune interfaces that define the pathology of ulcerative colitis. The most coherent evidence for translation into clinical practice for curcumin includes in combination with mesalamine, curcumin formulations enhanced by bioenhancing agents, resveratrol in small randomized trials, indigo naturalis, and Curcumin–QingDai. The best mechanistic evidence is based on microbial tryptophan metabolism, aryl hydrocarbon receptor signalling, interleukin 22 dependent epithelial repair, urolithin formation from ellagitannins, Nrf2 mediated redox defence, nuclear factor kappa B suppression, attenuation of the inflammasome, preservation of the mucus barrier, restoration of tight junctions and partial recovery of some short chain fatty acid producing microbial functions. In this review, we have collected the recent primary and translational studies available on microbiota/phytochemical interactions and merged them with compound-specific clinical and mechanistic evidence to suggest a development framework for precision medicine, including colonic exposure, microbial metabotype, mucosal pharmacodynamics, biomarker response, endoscopic healing, histology, and safety surveillance. The therapeutic window is optimum when phytochemicals are designed as colon targeted, microbiotically dependent pharmacologic interventions, instead of as broad-based anti-inflammatory dietary supplements.

European Journal Pharmaceutical and Medical Research
Openalex Percentile: Top 12%
Pomegranate: compositions and health benefits
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

GUT MICROBIOTA–PHYTOCHEMICAL INTERACTIONS IN ULCERATIVE COLITIS: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES — ED Padma, Balakoti Erothi*, Routhu Pratyusha, K Eswar Kumar · European Journal Pharmaceutical and Medical Research (2026) | TGRS Research Map | TGRS